It has now been two decades since the clinical high risk for psychosis (CHR) criteria were first formulated for the goal of preventing psychotic disorders, one of the most urgent unmet clinical needs in behavioral health, if not in all of medicine. As with most psychiatric patients, CHR patients benefit from psychotherapies but are also often left with important treatment needs not fully addressed or understood. Despite the critical public health need, drug development for CHR is viewed in many areas as risky, with the largest obstacle being identifying heterogeneity in the CHR patients.

In the Prodromal Network Outcomes project, ProNET, we will thoroughly phenotype 1,040 CHR across a network of 26 international sites with multi-modal biomarkers that include brain structure-function (MRI and EEG), psychopathology and cognition, genetics, body fluid analytes, natural speech/language, and passive/ecological momentary digital phenotyping, and map these biomarkers onto a core set of clinical outcome measures and trajectories over a treatment-time window of eight timepoints over 24 months. Specifically, the NIRL ProNET team at UNC Chapel Hill is one of the leading EEG teams by participant volume.